Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Alpha Cognition Inc (ACOG), Insmed (INSM) and Connect Biopharma Holdings (CNTB)

Tipranks - Tipranks - Thu Apr 9, 5:38AM CDT

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Alpha Cognition Inc (ACOG), Insmed (INSM) and Connect Biopharma Holdings (CNTB) with bullish sentiments.

Easter Sale - 70% Off TipRanks

Alpha Cognition Inc (ACOG)

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Alpha Cognition Inc, with a price target of $18.00. The company’s shares closed last Tuesday at $6.96.

According to TipRanks.com, Selvaraju is a 5-star analyst with an average return of 20.7% and a 52.1% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Santhera Pharmaceuticals Holding, MoonLake Immunotherapeutics, and Aardvark Therapeutics, Inc. ;'>

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Alpha Cognition Inc with a $18.00 average price target.

See the top stocks recommended by analysts >>

Insmed (INSM)

Mizuho Securities analyst Graig Suvannavejh reiterated a Buy rating on Insmed today and set a price target of $202.00. The company’s shares closed last Tuesday at $163.03.

According to TipRanks.com, Suvannavejh is a 5-star analyst with an average return of 19.5% and a 47.0% success rate. Suvannavejh covers the Healthcare sector, focusing on stocks such as Harmony Biosciences Holdings, Amylyx Pharmaceuticals Inc, and Neumora Therapeutics, Inc. ;'>

Currently, the analyst consensus on Insmed is a Strong Buy with an average price target of $214.71, a 31.9% upside from current levels. In a report issued on March 24, TipRanks – Google also upgraded the stock to Buy with a $159.00 price target.

Connect Biopharma Holdings (CNTB)

H.C. Wainwright analyst Brandon Folkes reiterated a Buy rating on Connect Biopharma Holdings today and set a price target of $7.00. The company’s shares closed last Tuesday at $2.82.

According to TipRanks.com, Folkes is a 1-star analyst with an average return of -1.7% and a 35.4% success rate. Folkes covers the Healthcare sector, focusing on stocks such as Sagimet Biosciences, Inc. Class A, Rani Therapeutics Holdings, and Milestone Pharmaceuticals. ;'>

Connect Biopharma Holdings has an analyst consensus of Strong Buy, with a price target consensus of $8.38, implying a 197.2% upside from current levels. In a report issued on March 31, Northland Securities also maintained a Buy rating on the stock with a $7.50 price target.

Read More on ACOG:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).